OKYO Pharma (OKYO) director awarded options for 6,500 shares at $1.85

Rhea-AI Filing Summary

OKYO Pharma Ltd director John P. Brancaccio received a grant of options over 6,500 common shares at an exercise price of $1.85 per share. These options were awarded on June 8, 2026 and are scheduled to become exercisable on June 8, 2027, expiring on June 8, 2036. Following this compensation-related grant, Brancaccio holds options over 138,394 shares in total.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BRANCACCIO JOHN P

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option	6,500	$1.85	$12K

Holdings After Transaction: Option — 138,394 shares (Direct, null)

Footnotes (1)

Key Figures

Option grant size: 6,500 options Exercise price: $1.85 per share Total options after grant: 138,394 options +2 more

5 metrics

Option grant size 6,500 options Grant of options over common shares on June 8, 2026

Exercise price $1.85 per share Strike price for newly granted options

Total options after grant 138,394 options Holdings following the reported transaction

Option vesting date June 8, 2027 Scheduled exercise start date

Option expiration date June 8, 2036 Final date to exercise granted options

Key Terms

Option, Common Shares, Grant, award, or other acquisition, exercise price, +1 more

5 terms

Option financial

"security_title: "Option""

Common Shares financial

"underlying_security_title: "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "1.8500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-08T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BRANCACCIO JOHN P

(Last) (First) (Middle)

14-15 CONDUIT ST

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option	$1.85	06/08/2026	06/08/2026	A		6,500		06/08/2027	06/08/2036	Common Shares	6,500	$1.85	138,394	D

Explanation of Responses:

Remarks:

Options vest 25% per year over four years beginning on the first anniversary of the grant date

	/s/ John Brancaccio	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did OKYO director John P. Brancaccio report on this Form 4 for OKYO?

Director John P. Brancaccio reported receiving a grant of options over 6,500 OKYO Pharma common shares. These options were awarded as a compensation-related grant, not an open-market purchase, and give him the right to buy shares at a fixed exercise price.

What is the exercise price of the options granted to OKYO director John P. Brancaccio?

The options granted to John P. Brancaccio have an exercise price of $1.85 per share. This means he can buy OKYO Pharma common shares at that price if he exercises the options once they become exercisable.

When do John P. Brancaccio’s newly granted OKYO Pharma options vest and expire?

The granted options are scheduled to become exercisable on June 8, 2027. They have an expiration date of June 8, 2036, giving a long window during which Brancaccio can choose to exercise them if he wishes.

How many OKYO Pharma options does John P. Brancaccio hold after the reported grant?

After the reported grant, John P. Brancaccio holds options over 138,394 OKYO Pharma shares. This total reflects his position in derivative securities following the 6,500-share option award disclosed in the Form 4 filing.

Was the OKYO Pharma Form 4 transaction an open-market buy or a compensation grant?

The Form 4 transaction for OKYO Pharma reflects a compensation-related grant, coded as a “Grant, award, or other acquisition.” It is not an open-market purchase, but an option award giving the director future rights to acquire shares.